Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.
DOWNLOAD NOWTLR7 ligand II is an orally bioavailable 8-hydroxyadenine analog that induces IFN production by binding to TLR7 on immune cells.1,2 It induces IFNα in human peripheral blood mononuclear cells with an EC50 value of 0.14 µM.2 At 10 µM, TLR7 ligand II was shown to reduce HCV levels by 60% in 24 hours in the human hepatocyte cell line Huh7, which carries a HCV replicon.3 It induces IFN in mice with a minimal effective dose of approximately 0.03 mg/kg, making it approximately 100-fold more potent than imiquimod (Item No. 14956).1
WARNING This product is not for human or veterinary use.
1. Synthesis and evaluation of 2-
2. Synthesis and immunostimulatory activity of 8-
3. Activation of anti-